Figure 6. (A) Survival outcome analysis in NSCLC patients with wild-type versus mutated PXN. Left and right graphs show overall and individual mutant survival curves, respectively. The relative expression of PXN, p-PXN, BCL-2, FAK, phospho-FAK, Cox IV, DRP-1, and MFN-2 was evaluated by IHC on two sets of samples; seven NSCLC patient samples bearing wild-type PXN and six NSCLC patient samples that were identified to have various PXN mutations as shown in (B). (C and D) represent the averaged staining intensity scores among all WT and all mutants. (E) Shows graph of staining intensity scores of the proteins assayed as expressed in the cytoplasm of the cells. (F)The panel shows photographs of IHC stains represented in one wild-type and one mutant sample.